Search PubMed⌕ Search

Biomedical subjects

K Minato

Publications and source records attributed to K Minato.

At least 181 records · Page 10Linked to original sources
PubMed1982

Comparative study of thallium emission myocardial tomography with 180 degrees and 360 degrees data collection.

Basic and clinical evaluation of thallium single-photon emission computed tomography (SPECT) using a rotating gamma camera with 180 degrees (LPO to RAO) data collection was carried out and compared with the full 360 degrees rotation. No attenuation correction was used. In a phantom study the reconstructed image from the 180 degrees scan revealed better resolution. Although the 180 degrees scan, when compared with the 360 degrees scan, showed great photon attenuation in the deep location of a line source in water, this problem was not significant in the clinical study of six normal hearts. In 11 cases with myocardial infarction, the perfusion defect was more clearly visualized in the 180 degrees scan. The defect-to-normal (D/N) wall-count ratio was lower in the 180 degrees scan (0.48 +/- 0.16; mean +/- s.d.) than in the 360 degrees scan (0.61 +/- 15, p less than 0.05), indicating superior lesion contrast in the former. These results suggest that for myocardial SPECT the 180 degrees collection method is a more effective technique in the clinical evaluation of coronary artery disease.

Coronary Circulation↗
PubMed1982

A novel pre-T cell line derived from acute lymphoblastic leukemia.

A cultured cell line, P30/Ohkubo with pre-T cell phenotype, was established from an 11-year-old girl with acute lymphoblastic leukemia (ALL). According to the morphological, cytochemical and immunological analyses, P30/Ohkubo was found to have common-ALL antigen, Ia-like antigen, pan-T cell antigen, and L2 morphology with localized acid phosphatase staining, but not rosette-forming capacity with sheep erythrocytes, B1 antigen or surface immunoglobulins. Chromosome analysis revealed that P30/Ohkubo had two constant marker chromosomes [11q +, del (9)], but lacked 14q +. These findings indicate that P30/Ohkubo is a novel cultured cell line of pre-T cell phenotype. These characteristics have remained unchanged for more than 20 months since establishment of the cell line.

Antigens, Surface↗
PubMed1982

[Prolactin releasing activity in serum of pregnant women and patients with galactorrhea-amenorrhea syndrome].

Serum samples obtained from 18 normal men and women, 24 pregnant women of the third trimester, and 8 patients with galactorrhea-amenorrhea syndrome (GAS) were subjected to a 3-phase methanol extraction. The serum extract released prolactin (PRL) specifically from rat anterior pituitary in vitro. The PRL releasing activity (PRA) was dependent on the incubation time and dose of serum extract, while independent on TRH or PRL in serum. The mean PRA in serum of pregnant women was significantly (p less than 0.02) higher than one of normal subjects. The mean PRA in serum of GAS was significantly higher than in pregnant women (p less than 0.05), and in normal subjects (p less than 0.001). When the individual PRL levels were compared to the PRA in samples from pregnant women and normal subjects, a significant (p less than 0.02) positive correlation evolved. These results indicate that a PRL releasing substance(s) distinct from TRH is (are) present in serum, and has (have) a relationship to the PRL concentration and late pregnant states.

Adult↗
PubMed1982

[A preliminary study of vincristine, methotrexate, and prednisolone (VM*P) combination chemotherapy for advanced adult non-Hodgkin's lymphoma].

The VM*P combination chemotherapy was administered to 13 patients with advanced (Stage III and IV) non-Hodgkin's lymphoma refractory to previous multiagent chemotherapy including cyclophosphamide (EX) and/or adriamycin (ADM). 1) Complete response was obtained in two patients with diffuse histiocytic lymphoma and one patient with diffuse undifferentiated (Burkitt type) lymphoma, and a response rate was 46.2%. 2) Tumor regression in responders was recognized within one week after administration of VM*P, but the duration of response was only 7(2-17) weeks in median (range). 3) Positive correlation was not seen between responsibility and dose of vincristine or methotrexate (MTX), but complete responders were obtained with only over 30 mg/dose of MTX. 4) In spite of resistant cases against EX and/or ADM, complete responders were obtained with VM*P therapy. Clinically, it was shown that cross resistance was minimal among MTX, EX and ADM. 5) Major side effects of VM*P therapy were myelosuppression (75%), hepatotoxicity (46%), and severe infection (23%). Neurotoxicity and nephrotoxicity were rare.

Adult↗